Mantle Cell lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight's, "Mantle Cell Lymphoma Pipeline Insight, 2024," report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Mantle Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Mantle Cell Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Mantle Cell Lymphoma Pipeline Outlook [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Mantle Cell Lymphoma Pipeline Report

* In October 2024:- Hoffmann-La Roche- The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
* In October 2024:- Loxo Oncology, Inc.- A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL). This study includes 3 parts: Phase 1 (pirtobrutinib monotherapy dose escalation and dose expansion), Phase 1b (pirtobrutinib combination therapy dose expansion), and Phase 2 (pirtobrutinib monotherapy dose expansion).
* DelveInsight's Mantle Cell Lymphoma pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Mantle Cell Lymphoma treatment.
* The leading Mantle Cell Lymphoma Companies such as AbbVie, Takeda, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company Ltd, BeiGene, Gilead Sciences, and others.
* Promising Mantle Cell Lymphoma Therapies such as Obinutuzumab, Glofitamab, Pirtobrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib, Tafasitamab , and others.

Stay ahead with the most recent pipeline outlook for Mantle Cell Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Mantle Cell Lymphoma Treatment Drugs [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Mantle Cell Lymphoma Emerging Drugs Profile

* Venetoclax: AbbVie

Venetoclax is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.

* Ixazomib: Takeda

Ixazomib belongs to a class of drugs called proteasome inhibitors, which work by blocking the action of proteasomes, cellular structures responsible for breaking down proteins. By inhibiting proteasomes, ixazomib helps to disrupt the growth and survival of cancer cells. Currently, the product is in the Phase II stage of its development for the treatment of mantle cell lymphoma.

* ADI-001: Adicet Bio

ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent antitumor activity in preclinical models, leading to long-term control of tumor growth. ADI-001 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in the Phase I stage of its development for the treatment of mantle cell lymphoma.

Explore groundbreaking therapies and clinical trials in the Mantle Cell Lymphoma Pipeline. Access DelveInsight's detailed report now! @ New Mantle Cell Lymphoma Drugs [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Mantle Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Mantle Cell Lymphoma Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Unveil the future of Mantle Cell Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Mantle Cell Lymphoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Mantle Cell Lymphoma Pipeline Report

* Coverage- Global
* Mantle Cell Lymphoma Companies- AbbVie, Takeda, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company Ltd, BeiGene, Gilead Sciences, and others.
* Mantle Cell Lymphoma Therapies- Obinutuzumab, Glofitamab, Pirtobrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib, Tafasitamab, and others.
* Mantle Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Mantle Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Mantle Cell Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Mantle Cell Lymphoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Mantle Cell Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Mantle Cell Lymphoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Venetoclax: AbbVie
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Ixazomib: Takeda
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ADI-001: Adicet Bio
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Mantle Cell Lymphoma Key Companies
* Mantle Cell Lymphoma Key Products
* Mantle Cell Lymphoma- Unmet Needs
* Mantle Cell Lymphoma- Market Drivers and Barriers
* Mantle Cell Lymphoma- Future Perspectives and Conclusion
* Mantle Cell Lymphoma Analyst Views
* Mantle Cell Lymphoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mantle-cell-lymphoma-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/